Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

Benha University

Status: Completed

Conditions: Hepatitis C

Treatments: Biological: Blood Sampling

Study type: Observational

Funder types: Other

Identifiers

NCT05449847

RC 1.7.2021

Details and patient eligibility

About

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.

Enrollment: 100 patients

Sex: All

Ages: 31 to 67 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Complicated hepatitis C by HCC
• Complicated hepatitis C by liver cirrhosis
• Complicated hepatitis C by steatohepatitis
• uncomplicated hepatitis C

Exclusion criteria

• pre-portal fibrosis secondary to previous bilharzial disease
• pre-portal fibrosis secondary to alcoholic fatty liver
• The presence of hepatic malignancy other than HCC
• decompensated cirrhosis
• hepatorenal failure
• hepatic manifestations of congestive heart failure.

Trial design

100 participants in 2 patient groups

Complicated HCV

Treatment:

Biological: Blood Sampling

Non Complicated HCV

Treatment:

Biological: Blood Sampling